Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 10.6% in the morning session after Piper Sandler ...

Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its ...

Fintel reports that on March 12, 2025, Piper Sandler upgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Neutral ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Myriad Genetics (MYGN) stock was upgraded to Overweight by Piper Sandler, citing a balanced risk-reward set up for its beaten ...

Piper Sandler upgraded Myriad Genetics (MYGN) to Overweight from Neutral with a price target of $12.50, up from $11.50. The stock is down more ...

Morgan Stanley lowered the firm’s price target on Myriad Genetics (MYGN) to $16 from $21 and keeps an Equal Weight rating on the shares after ...

Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its price objective decreased by Bank of America from $13.00 to $11.00 in ...

UnitedHealthcare will stop covering Myriad Genetics' GeneSight test in 2025, impacting $45 million in revenue. Myriad ...

Myriad Genetics has a 1-year low of $9.76 and a 1-year high of $29.30. Myriad Genetics ( NASDAQ:MYGN – Get Free Report ) last issued its earnings results on Tuesday, February 25th.

Good day, and thank you for standing by. Welcome to the Myriad Genetics Fourth Quarter 2024 Financial Earnings Conference Call. At this time, all participants are in a listen-only mode.

Myriad Genetics (NASDAQ:MYGN) has been analyzed by 10 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of ...